Enterome SA, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, will present positive data from its Phase 1/2 clinical study with...

Enterome SA, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, announces it will present new positive data from its ongoing...

Breakthrough study published in Frontiers in Immunology demonstrates CIT-013’s effectiveness against additional types of extracellular traps, expanding potential therapeutic...

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated...

Cmbio™, a global leader in multi-omics science and digital biology, announces a strategic partnership with Nimble Science, to deliver first in class high-quality, multi-omic...

Cmbio®, a global leader in multi-omics science and digital biology, is pleased to announce the purchase of the e[datascientist]™ software platform through an Asset Sale...

The study met its primary endpoint with a significant gastrointestinal overall response rate at Day 28 of 62% and demonstrates the unprecedented efficacy of MaaT013 as...

These findings underscore MaaT013’s potential as a transformative therapy for aGvHD, a condition with poor survival rates and limited treatment options. The high response...

Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), announces...